NoelLaudiMDMRCP
Oncology • Coon Rapids, MNhemonc doc, Oncology Director. Mercy Hospital. Coon Rapids. MN 55433.
Dr. Laudi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11850 Blackfoot St NW
Ste 300
Coon Rapids, MN 55433Phone+1 763-236-0808Fax+1 763-236-6065
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2002 - 2005- University of MinnesotaFellowship, Hematology and Medical Oncology, 1998 - 1998
- University of MinnesotaResidency, Internal Medicine, 1995 - 1998
University of Malta School of MedicineClass of 1992
New LyceumBS, Physics, Chemistry, Biology, Philosophy, 1984 - 1987
Certifications & Licensure
MN State Medical License 1998 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Best Diagnostician Award Interal Medicine Residency Program, University of Minnesota, 1998
Clinical Trials
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Publications & Presentations
PubMed
- 3 citationsPhase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack
Clinical Cancer Research. 2023-09-15 - 161 citationsCombination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen
Journal of Clinical Oncology. 2023-01-10 - 8 citationsE3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination With High-Dose Interferon-α2b in Advanced MelanomaAhmad A. Tarhini, Sandra J. Lee, Xiaoxue Li, Uma N. M. Rao, Arun Nagarajan
Clinical Cancer Research. 2019-01-15
Journal Articles
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
- Efficacy of high dose therapy and hematopoietic stem cell transplantation for mantle cell lymphomaLaudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Bohac J, Rogers T, Coad J, Weisdorf DJ, American Journal of Hematology, 1/1/2006
- Postoperative severe microangiopathic hemolytic anemia associated with a giant hepatic cavernous hemangiomaBanton KL, D’Cunha J, Laudi N, Flynn C, Hammerschmidt D, Humar A, Sielaff T, J Gastrointest Surg, 5/1/2005
- Join now to see all
Abstracts/Posters
- Long term follow-up after autologous hematopoietic stem cell transplantation for low- grade non-Hodgkin’s lymphomaLaudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ, ASCO meeting, New Orleans, 6/1/2004
- Differentiation between Thrombotic Thrombocytopenic Purpura and HELLP SyndromeLaudi N., Jaffe J and Hyde B., American College of Physicians Minnesota Chapter Meeting, 11/1/1997
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
